Compare Hasbro, Inc. (HAS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs TG Therapeutics Inc — how do they compare? Hasbro, Inc. trades at $97.28 (market cap $13.69B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Hasbro, Inc. is the larger of the two by market cap, and Hasbro, Inc. pays a 2.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAS | TGTX | |
|---|---|---|
Market Cap | $13.69B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $59.06 |
52-Week Low | $70.95 | $26.94 |
Enterprise Value | $15.88B | $7.84B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.915, up 0.45% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a 64.41% gross margin and 167.83% ROE, though 2025 net income was negative. Analyst consensus is a Buy with a $104.90 price target, and recent news highlights growth in Magic: The Gathering and new content launches.
Outlook is positive driven by franchise strength and digital gaming, but risks include margin pressures, high debt, and competitive threats. The stock offers a 2.93% dividend yield and is near its 52-week high, suggesting cautious optimism for continued upside if execution remains solid.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
